Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
Abstract
Antibody-drug conjugates have emerged as a promising cancer treatment, combining targeted delivery of cytotoxic agents with the specificity of monoclonal antibodies. Despite their potential, ADCs face limitations such as resistance and off-target effects. To enhance their efficacy, ADCs are increasingly being combined with other therapeutic strategies, including immune checkpoint inhibitors, chemotherapy, small-molecule inhibitors, anti-angiogenic agents, and CAR-T cell therapies. These combination therapies aim to overcome resistance mechanisms, improve tumor targeting, and boost immune responses. Clinical studies have shown that such combinations can significantly improve response rates and progression-free survival across various cancers. This review explores the mechanisms, clinical efficacy, key studies, challenges, and future perspectives of Antibody-drug conjugates combinations in cancer therapy.
Read the paper
Related studies
- Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2)
- In silico and in vitro studies: investigating the chemical composition, DFT, molecular docking, and dynamic simulation of Satureja candidissima (Munby) Briq essential oil as a potential antibacterial agent
- Quercetin combined with ciprofloxacin and gentamicin inhibits biofilm formation and virulence in Staphylococcus aureus
- In silico study of the mechanism of action, pharmacokinetic and toxicological properties of some N-methylanthranilates and their analogs
- Anticonvulsant Effects of Citronellal, Daidzin, and Phytol, Possibly Through GABAA Receptor and Voltage-Gated Sodium Channel Interaction Pathways: In Vivo and In Silico Studies
- 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as D3R-Selective Ligands for 3D-QSAR, Docking and Molecular Dynamics Simulation Studies
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.